Marianna Fedorenko (@mariannaw)

New York State Department of Health Confirms Most Flu Cases Ever Recorded in One Week

How bad is the flu? Worst since NY health dept began recording in 2004. Current: 189,312 positive cases in NY so far.
Hospitalizations up 63% from previous week, to 3,666.

#Medsky #IDsky #epidemiology #vaccines #influenza #immunology

27.12.2025 22:46 👍 14 🔁 8 💬 1 📌 3

Unlocking potentials: the impact of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam in combating carbapenem-resistant Enterobacter cloacae ABSTRACTCarbapenem-resistant Enterobacterales (CREs) are recognized as an urgent public threat by the Centers for Disease Control and Prevention. This study assesses the activity of humanized serum concentrations for meropenem (2 g Q8h), meropenem-vaborbactam (4 g Q8h), and ceftazidime-avibactam (2.5 g Q8h) against carbapenemase-producing (CP) (AR-1046blaKPC-3) and non-CP (AR-8bla ACT-15) Enterobacter cloacae isolates in a 120 h in vitro pharmacodynamic model. Additionally, we compared antimicrobial administration as a bolus or extended infusion for each isolate and treatment. For the CP strain, all treatments with meropenem-vaborbactam and ceftazidime-avibactam were bacteriostatic through 24 h. Extended-infusion meropenem-vaborbactam exhibited the most prolonged bacteriostatic activity and was significantly more effective than ceftazidime-avibactam at 120 h (0.92 log10 lower mean colony count compared to extended-infusion ceftazidime-avibactam, P < 0.001). For the non-CP strain, all simulated treatments demonstrated initial bactericidal activity through 24 h, except for ceftazidime-avibactam bolus administration. Meropenem and meropenem-vaborbactam, administered as bolus dosing, each maintained significantly greater bacterial colony count reductions compared to extended infusion through 120 h against non-CP CRE (P < 0.01). No significant differences were found between bolus and extended infusion for ceftazidime-avibactam (P = 0.08). Resistance development was observed following treatment with meropenem monotherapy (minimum inhibitory concentrations increasing to >32 µg/mL for the non-CP isolate with extended infusion and to >32 µg/mL for the CP isolate with bolus and extended-infusion treatments) and ceftazidime-avibactam (minimum inhibitory concentration increase from 2 to 16 μg/mL with bolus dosing against the CP isolate). Meropenem-vaborbactam exposure did not result in the emergence of antimicrobial resistance in any of the tested models.

CRE study: Meropenem-vaborbactam 🚀 best vs CP strain (0.92 log10⬇️ at 120h, P<0.001); bolus dosing 👊 better vs non-CP; resistance seen in meropenem & ceftazidime-avibactam, not vaborbactam.

#idsky

07.12.2025 03:30 👍 2 🔁 1 💬 0 📌 0

🆕 MMWR: In NYC, NDM-CRE just surpassed KPC-CRE for the first time.

And nearly 75% of these cases had no long-term care facility link

This is a changing landscape of antibiotic resistance - happening across US

#IDSky
📄: www.cdc.gov/mmwr/volumes...

10.07.2025 17:10 👍 8 🔁 3 💬 3 📌 1

Propensity score-weighted analysis of the impact of outpatient parenteral antimicrobial therapy (OPAT) plan reconciliation on unscheduled care Outpatient parenteral antimicrobial therapy (OPAT) is a mechanism for delivery of antimicrobial therapy outside of inpatient care; however, risks associated with OPAT combined with transition-of-care vulnerabilities may result in unscheduled healthcare use. On 6/15/2020, our institution launched a program entailing OPAT plan review and reconciliation by infectious diseases (ID) pharmacists prior to hospital discharge. We analyzed the frequency of all-cause 90-day emergency department (ED) visits, readmissions, and mortality of patients pre- and post-implementation of OPAT plan reconciliation.MethodsUnique, adult OPAT recipients discharged to home or a post-acute care facility from an academic hospital before (6/1/2017-6/14/2020) and after (6/15/2020-6/30/2022) implementation of ID pharmacist review and reconciliation of OPAT plans were included. We performed a propensity score-weighted analysis to compare 90-day outcomes pre- and post-intervention while adjusting for relevant clinical characteristics. We accounted for missing data by using multiple imputation.ResultsA total of 2408 OPAT patients met inclusion criteria: 1650 pre-implementation and 758 post-implementation. Patients in the post-implementation group had statistically fewer ED visits (pre: 22.2%; post: 17.8%; p = 0.02) and hospital readmissions (pre: 38.9%; post: 33.4%; p = 0.01) within 90 days after discharge from index admission when compared to the pre-implementation cohort. There was no significant difference in the 90-day all-cause mortality between cohorts.ConclusionsFollowing implementation of OPAT plan reconciliation by ID pharmacists prior to discharge to home from acute care, OPAT recipients were significantly less likely to experience 90-day ED visits or 90-day readmissions.

📉 OPAT plan review by ID pharmacists reduced 90-day ED visits from 22.2% to 17.8% (p=0.02) & readmissions from 38.9% to 33.4% (p=0.01). No change in mortality. 🏥

#idsky

12.06.2025 23:30 👍 4 🔁 1 💬 0 📌 0

MDR-GNB infections remain a major global health challenge. With new diagnostics & antibiotics emerging, we’re at a crossroads.
Fantastic 🆕💫review about MDR GN by Dr. Nenad Macesic
Figures🌟 #idsky
www.thelancet.com/journals/lan...

22.01.2025 15:21 👍 24 🔁 6 💬 4 📌 0

#IDsky

Winter is coming, and so is influenza! Reminder to get your flu shot 💉 if you haven’t already.

Folks, it’s starting. Be ready.

gis.cdc.gov/GRASP/Fluvie...

12.12.2024 01:08 👍 41 🔁 9 💬 2 📌 2

Feel better!!

11.12.2024 20:18 👍 1 🔁 0 💬 1 📌 0

Happy Thanksgiving to you too!

27.11.2024 21:48 👍 1 🔁 0 💬 0 📌 0

Happy Antibiotic Awareness Week! #IDSky #MedSky #Stewardship

18.11.2024 14:42 👍 9 🔁 3 💬 0 📌 0

Global distribution of KPC (A), NDM (B), and OXA-48-like (C) carbapenemases.

Phenotypic and immunochromatographic assays for the detection of carbapenemase-producing carbapenem-resistant organisms.

Selecting a carbapenemase confirmation test for suspect clinical isolates based on cost and complexity

Appearance of carbapenem-resistant organisms on selective chromogenic media.

Laboratory detection of carbapenemases among Gram-negative organisms

Patricia Simner, Johan Pitout, and Tanis Dingle 🤩

#ClinMicroReviews

journals.asm.org/doi/10.1128/... (Paywall) #IDSky #MicroSky

15.11.2024 16:41 👍 50 🔁 14 💬 2 📌 1

a woman is making a funny face with her mouth open and her eyes closed . ALT: a woman is making a funny face with her mouth open and her eyes closed .

Thats horrifying

14.11.2024 14:38 👍 1 🔁 0 💬 0 📌 0

What?!? I knew there was a book 2 but not 3 or 4. Now, I will have to go read them. Thank you!

13.11.2024 01:51 👍 0 🔁 0 💬 0 📌 0

What's up, IDSky?

08.11.2024 21:45 👍 70 🔁 8 💬 11 📌 3

The Upper East Side has great places to eat- I used to live there. Try Amarena, 83 1/2, JoJo by Jean-Georges, Caledonia (bar); coffee: Hutch and Waldo, 787 coffee, Sant Ambroeus (coffee shop inside Sotheby’s), gelato: Anita gelato

11.11.2024 17:33 👍 1 🔁 0 💬 0 📌 0

sharing some starter packets curated by @timomoilanen.bsky.social and @germhuntermd.bsky.social

Genomic epidemiology: go.bsky.app/AZgp9Ko
IDSky 1: go.bsky.app/LnAQjdq
IDSky 2: go.bsky.app/JNfSvQT
Epidemiologists of Bluesky: go.bsky.app/3cn51fN
AMR: go.bsky.app/KkZfvrh

08.11.2024 17:53 👍 20 🔁 11 💬 1 📌 0

Marianna Fedorenko

Latest posts by Marianna Fedorenko @mariannaw